Humana Inc. (NYSE:HUM) Holdings Cut by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 19.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 53,738 shares of the insurance provider's stock after selling 13,324 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Humana were worth $13,634,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new stake in Humana during the 3rd quarter valued at $31,000. FPC Investment Advisory Inc. acquired a new stake in Humana during the 4th quarter valued at $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the 4th quarter valued at $30,000. OFI Invest Asset Management purchased a new position in shares of Humana during the 4th quarter worth $33,000. Finally, Atwood & Palmer Inc. lifted its stake in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Up 0.5 %

Shares of Humana stock traded up $1.38 during trading hours on Friday, hitting $253.11. 1,331,284 shares of the company's stock traded hands, compared to its average volume of 1,716,373. The stock has a 50 day simple moving average of $271.37 and a 200-day simple moving average of $280.01. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market cap of $30.55 billion, a PE ratio of 25.44, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.40%. Humana's dividend payout ratio (DPR) is 35.58%.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on HUM shares. Truist Financial increased their price target on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Royal Bank of Canada reissued an "outperform" rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Morgan Stanley reduced their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, Barclays increased their target price on Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Humana has an average rating of "Hold" and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.